High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 5.
Figure 5.

CD276 is an immune gene with elevated expression in GSCs. (A) 3D genome and chromatin landscape at the CD276 locus. This panel integrates CTCF ChIP-seq, H3K27ac ChIP-seq, RNA-seq, compartments (50-kb), domains (10-kb), and loops (union of 5-, 10-, and 25-kb calls) determined by Hi-C for three patient-derived GSC cultures (G523, G567, and G583). (B) Expression of CD276 was determined by RNA-seq in bulk GBM samples (n = 76), GSCs (n = 76), and non-neoplastic brain tissue (n = 4). P-values were calculated with the Mann–Whitney U statistical test. (C) Survival of glioma patients stratified by CD276 expression in the French data set. Median gene expression was used to stratify patients. P-value was derived with log-rank statistics. Shading around curve indicates 95% confidence interval. (D) Patterns of expression of CD276 in the prenatal and postnatal human brain. Data were extracted from BrainSpan.

This Article

  1. Genome Res. 29: 1211-1222

Preprint Server